PCF Young Investigator Awards are intended to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas and offer career and project support for early career physicians and scientists who are committed to advancing the prostate cancer field. Thirty-four PCF Young Investigator Awards totaling $7.2 million were granted to the promising next generation of cancer researchers.
Joining the PCF community instantly opens up a wealth of collaborative opportunities which will enrich the support network that NDS provides me as a young investigator to produce clinically relevant scientific results
- Dr Dimitrios Doultsinos
Dr Doultsinos received the 2022 CRIS Cancer Foundation, Eustace Wolfington and Larry Leeds – PCF Young Investigator Award for his project, 'Exploring Synthetic Lethality of Targeting miR346-Unfolded Protein Response Dependent DNA Damage Response Mechanisms in Treatment-Resistant Prostate Cancer'.
Altered stress response pathways are a hallmark of cancer which allows tumour cells to rapidly grow and avoid normal death signals; however, these alterations may also create sensitivities that can be therapeutically targeted.
The award will provide support for Dr Doultsinos to investigate the biology of the unfolded protein response in prostate cancer. He will determine whether these alterations may act as biomarkers for sensitivity to certain treatments, or may be promising therapeutic targets themselves.
“I feel privileged to win a PCF Young Investigator Award, joining an extremely talented class of 2022," said Dr Doultsinos. "Joining the PCF community instantly opens up a wealth of collaborative opportunities which will enrich the support network that NDS provides me as a young investigator to produce clinically relevant scientific results.
Read more about Dr Doultsinos's research and the PCF Young Investigator Awards on the Prostate Cancer Foundation website.
Dimitrious Doultsinos (centre) on stage with the other recipients at the 2022 PCF Young Investigator Award ceremony.
Howard Soule (PCF Chief Science Officer and Executive Vice President) and Dimitrious Doultsinos.